Trailing Twelve Months Revenue Growth: Zevra Corp (ZVRA)

Public company logo of Zevra Corp (ZVRA)

Zevra Therapeutics (ZVRA) is developing therapies for rare pathologies through partnerships with scientific foundations. An environmental approach and bioethics in drug development support the TTM revenue growth trajectory compared to last year, where the indicator remains around 75.00. Business stability is ensured by diversified supply chains for specific components, guaranteeing the uninterrupted distribution of medications.

Zevra Therapeutics (ZVRA): Revenue Growth YoY (Last 12 Months) from 02/11/2024 to 11/18/2026

Zevra Corp (ZVRA) - metric breakdowns and financial figures

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Fundamental company valuation:Zevra Corp (ZVRA)
Finished products of Kempharm

Zevra Therapeutics (ZVRA) maintains absolute pricing power within the essential rare disease medication segment, ensuring high cash flow stability. This metric measures the percentage change in revenue over the last twelve months relative to the same period last year, while the TTM revenue growth rate allows investors to filter out short-term volatility and assess the long-term effectiveness of asset commercialization.